As China continues to inch ahead of competition in terms of trial initiations, immunology and metabolic disease trials attract sponsor eyes.
China has continued its new-found leadership in the clinical trials space into Q1 2026. Credit: OnePixelStudio / Shutterstock.com.
As 20 May marks Clinical Trials Day 2026, the ‘Research Rising’ theme has never seemed so apt, as trial initiations in Q1 2026 saw an uptick, with key R&D player China continuing to cultivate its dominance within the clinical trials landscape.
According to GlobalData’s Pharmaceutical Intelligence Center, the number of global Phase I-III trials initiated in Q1 2026 rose 1.3% compared with the same quarter in 2025. Of these new studies, China was responsible for a third of those trials, while the country also posted a 6.5% year-on-year (YoY) growth in study debuts. Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
